COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00AQP
|
|||
| Drug Name |
Ribavirin + interferon alfa-2a
|
|||
| Synonyms |
Rebetol + roferon A
|
|||
| Drug Type |
Combination drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [2] |
| Ribavirin is a nucleoside against MERS-CoV. Its mechanism includes lethal mutagenesis of RNA virus genomes mediated by the MERS-CoV RNA-dependent RNA polymerase. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. | |||
| 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.